SCB Engages Cell and Gene Therapy Community at CASSS Inaugural Meeting
Washington, DC (July 13, 2018) — On July 10-12, professional scientific society CASSS held its inaugural Cell & Gene Therapy Products (CGTP): Manufacturing, Quality and Regulatory Considerations meeting in Rockville, Maryland. The meeting was held in response to the need expressed at CASSS’s 2017 Summer CMC Forum for an ongoing dialogue and exchange of scientific and technical advances that are the basis of evolving regulatory practices for a diverse array of innovative cell and gene therapy products.
SCB was an exhibitor partner at the event, interacting with cell and gene therapy community at their table and running a session with 170 people. During the session, Kendra Chappell, a Director at SCB partner Nexight Group, provided an overview of SCB and reviewed recommendations for improving processes and criteria for regenerative medicine standards development. In addition, participants filled out worksheets and asked questions sharing what they felt would be useful information and tools to improve engagement and information sharing across the community. SCB will use this information to coordinate and facilitate better information sharing and regenerative medicine standards advancement.
In addition, SCB President Jiwen Zhang gave a presentation and spoke on a panel where she discussed what SCB is doing to address the need for standards development in the CGTP space. These include projects on:
Characterizing fiber-based scaffolds (in partnership with ASTM, NIST, BioFabUSA)
Evaluating pre-existing immunity standards (an ARM S&T A-gene project)
To learn more about how you can get involved these projects and others like them, contact SCB’s Senior Technical Program Manager Dawn Henke at dhenke@regenmedscb.org or sign up for our e-newsletter (below).